SAB Biotherapeutics Inc
SABS
NASDAQ
Biotechnology
$3.70
USD
-0.05 (-1.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $345.75M
Volume 324.1K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-12.78M
TTM
+65.5%
YoY
Operating Cash Flow
$-53.94M
TTM
-75.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | — | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.7 | 3.7 | 5.0 | 6.6 | 7.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.7 | 12.7 | 15.8 | 20.0 | 23.4 |
Operating Income | -9.7 | -12.7 | -15.8 | -20.0 | -23.4 |
EBITDA | -9.0 | -11.9 | -15.0 | -19.3 | -22.6 |
Other Income / Expense | -0.3 | 57.5 | -1.7 | 0.1 | -0.8 |
Total Other Income / Expense | -0.4 | 58.1 | -1.1 | 1.1 | 0.9 |
Income Before Income Taxes | -10.1 | 45.4 | -16.9 | -18.9 | -22.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -10.1 | 45.4 | -16.9 | -18.9 | -22.5 |
Consolidated Net Income / Loss | -10.1 | 45.4 | -16.9 | -18.9 | -22.5 |
Net Income Attributable to Common Shareholders | -10.1 | 5.3 | -2.8 | -18.9 | -22.5 |
Basic EPS | -$1.09 | $0.50 | -$0.06 | -$0.35 | -$0.28 |
Diluted EPS | -$1.09 | -$0.21 | -$0.02 | -$0.35 | -$0.28 |
Basic Shares Outstanding | 9.3M | 10.7M | 48.0M | 53.6M | 79.8M |
Diluted Shares Outstanding | 9.3M | 77.9M | 148.9M | 53.6M | 79.8M |